TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $55.00 at B. Riley

Key Points

• B. Riley has increased the target price for TG Therapeutics (NASDAQ:TGTX) from $53 to $55, indicating a potential upside of 70.58% from its previous close, while maintaining a "buy" rating.
• Goldman Sachs recently upgraded TG Therapeutics to a "hold" rating with a target price set at $37.00, contributing to a consensus rating of "Moderate Buy" among analysts.
• Despite a quarterly earnings miss, TG Therapeutics reported a 92.1% year-over-year revenue increase, posting $141.15 million in revenue for the quarter.

TG Therapeutics (NASDAQ:TGTX - Free Report) had its price objective boosted by B. Riley from $53.00 to $55.00 in a report released on Wednesday morning, MarketBeat reports. They currently have a buy rating on the biopharmaceutical company's stock. B. Riley also issued estimates for TG Therapeutics' Q3 2025 earnings at $0.25 EPS, Q4 2025 earnings at $0.33 EPS, FY2025 earnings at $0.84 EPS, FY2026 earnings at $1.74 EPS, FY2027 earnings at $2.13 EPS and FY2029 earnings at $4.44 EPS.

Separately, The Goldman Sachs Group upgraded shares of TG Therapeutics to a "hold" rating and set a $37.00 target price on the stock in a report on Thursday, July 10th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, TG Therapeutics has an average rating of "Moderate Buy" and an average target price of $48.00.

TG Therapeutics Price Performance

Shares of TG Therapeutics stock traded down $0.24 on Wednesday, hitting $32.37. The company's stock had a trading volume of 3,197,005 shares, compared to its average volume of 2,006,223. The company has a market capitalization of $5.14 billion, a P/E ratio of 87.49 and a beta of 1.88. The company has a quick ratio of 2.96, a current ratio of 3.86 and a debt-to-equity ratio of 0.89. The firm has a fifty day moving average price of $31.91 and a 200-day moving average price of $35.65. TG Therapeutics has a 52-week low of $21.16 and a 52-week high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). The firm had revenue of $141.15 million during the quarter, compared to analysts' expectations of $147.76 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. TG Therapeutics's revenue for the quarter was up 92.1% on a year-over-year basis. During the same quarter last year, the company posted $0.04 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS. On average, equities research analysts expect that TG Therapeutics will post 0.08 earnings per share for the current fiscal year.

Insider Transactions at TG Therapeutics

In related news, Director Sagar Lonial sold 20,852 shares of the stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total transaction of $672,268.48. Following the completion of the sale, the director owned 94,061 shares of the company's stock, valued at approximately $3,032,526.64. This represents a 18.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 10.64% of the company's stock.

Institutional Trading of TG Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of TGTX. CWM LLC grew its holdings in TG Therapeutics by 16.2% during the first quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company's stock worth $82,000 after acquiring an additional 290 shares during the period. Teacher Retirement System of Texas grew its holdings in TG Therapeutics by 1.0% during the second quarter. Teacher Retirement System of Texas now owns 40,212 shares of the biopharmaceutical company's stock worth $1,447,000 after acquiring an additional 417 shares during the period. Golden State Wealth Management LLC grew its holdings in TG Therapeutics by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 433 shares during the period. Kingswood Wealth Advisors LLC grew its holdings in TG Therapeutics by 6.4% during the second quarter. Kingswood Wealth Advisors LLC now owns 8,284 shares of the biopharmaceutical company's stock worth $298,000 after acquiring an additional 500 shares during the period. Finally, Louisiana State Employees Retirement System grew its holdings in TG Therapeutics by 0.8% during the second quarter. Louisiana State Employees Retirement System now owns 63,400 shares of the biopharmaceutical company's stock worth $2,282,000 after acquiring an additional 500 shares during the period. Institutional investors and hedge funds own 58.58% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.